Lifeline Biotechnologies, Inc. Receives Update on Development Status of First Warning System™

RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (Pink Sheets:LLBT) today announced that the Company will be meeting with the Managing Engineer of Nanyang Technical University this week to receive an update on the development status of the First Warning System™ (FWS). The expected advancements could facilitate women who have periodic FWS breast examinations by classifying them as normal, suspicious or positive for breast cancer.

The underlying technology, upon which the FWS is based, holds the possibility of eliminating over 90 percent of unnecessary breast biopsies performed each year in the U.S. providing a potential savings of up to $2.8 billion annually. The First Warning System™ could also conceivably eliminate the need for many of the newly suggested MRIs thereby providing additional savings.

“We look forward to meeting with the Managing Engineer to review their findings to date. This information will be needed to support Lifeline's application for the 510(k). Upon clearance of the 510(k) by the U.S. Food and Drug Administration (FDA), Lifeline could begin marketing the First Warning System™,” stated Jim Holmes, CEO of Lifeline Biotechnologies, Inc.

Lifeline recently announced that the Company has been in discussions with various firms to help with the preparation of filing the 510(k) with the FDA. The selected firm will help with the verification and validation guidelines, and the Company expects to announce its selection soon.

About Lifeline Biotechnologies, Inc:

Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System™, which was designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: the development of the First Warning System™, the completion of clinical trials and FDA pre-marketing clearance. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact:

Lifeline Biotechnologies, Inc.
Investor Relations 
1-886-THE APPL(E)
www.lbti.com